focus -WSS

focus

author：focus 2025-09-30 18:47:56 - browse：311

Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： A virus, fished out of a lake, may have saved a man’s life

knowledge

entertainment

WSS

FTX founder Sam Bankman

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Bill would stop addiction treatment from triggering child abuse inquiry

Was Amgen transparent enough on FDA's concern on cancer drug?

Physician executives need more than on

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

hotspot

focus

explore

Medicare proposal to cover medical devices draws a mixed reaction

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

At least 13 dead in Texas as scorching temps continue

More regulation could be coming for drug ads

How one medical school became remarkably diverse

Zapping the brain for stroke rehab: Pivotal clinical trial begins

23andMe had bad news about my health. I wish a person had delivered it

AI can decode, harness the power of the humane immune system

Virginia high school admissions case could be legal follow

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

explore

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Wegovy cuts risk of cardiovascular events by 20%, study finds

Sana to lay off nearly a third of staff, de

Choosing scientific sides in the fight against Alzheimer's

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Why Charlie Gard's case is so disturbing to Americans

entertainment

knowledge

entertainment

hotspot